These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36907828)

  • 1. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
    Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
    Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis.
    Annabi MS; Carter-Storch R; Zaroui A; Galat A; Oghina S; Kharoubi M; Bezard M; Derumeaux G; Fanen P; Lemonnier F; Poullot E; Itti E; Gallet R; Teiger E; Pibarot P; Damy T; Clavel MA
    J Am Heart Assoc; 2024 Jul; 13(13):e034723. PubMed ID: 38904242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Castaño A; Heitner SB; Masri A; Huda A; Calambur V; Bruno M; Schumacher J; Emir B; Isherwood C; Shah SJ
    J Card Fail; 2024 Jun; 30(6):778-787. PubMed ID: 38065306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.
    Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.
    Lindmark K; Pilebro B; Sundström T; Lindqvist P
    ESC Heart Fail; 2021 Feb; 8(1):745-749. PubMed ID: 33205581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.
    Inomata T; Tahara N; Nakamura K; Endo J; Ueda M; Ishii T; Kitano Y; Koyama J
    ESC Heart Fail; 2021 Aug; 8(4):2647-2659. PubMed ID: 34137515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting transthyretin amyloid cardiomyopathy (ATTR-CM) using machine learning: an evaluation of the performance of an algorithm in a UK setting.
    Tsang C; Huda A; Norman M; Dickerson C; Leo V; Brownrigg J; Mamas M; Elliott P
    BMJ Open; 2023 Oct; 13(10):e070028. PubMed ID: 37899155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model.
    Bruno M; Sheer R; Reed C; Schepart A; Nair R; Simmons JD
    J Manag Care Spec Pharm; 2023 May; 29(5):530-540. PubMed ID: 37121249
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis.
    Kharoubi M; Roche F; Bézard M; Hupin D; Silva S; Oghina S; Chalard C; Zaroui A; Galat A; Guendouz S; Canoui-Poitrine F; Hittinger L; Teiger E; Lefaucheur JP; Damy T
    ESC Heart Fail; 2021 Apr; 8(2):1656-1665. PubMed ID: 33354901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
    López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P
    Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553
    [No Abstract]   [Full Text] [Related]  

  • 17. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
    Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
    JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.
    Bay K; Gustafsson F; Maiborg M; Bagger-Bahnsen A; Strand AM; Pilgaard T; Poulsen SH
    ESC Heart Fail; 2022 Jun; 9(3):1524-1541. PubMed ID: 35343098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.
    Hänselmann A; Berliner D; Bauersachs J; Bavendiek U
    Herz; 2022 Aug; 47(4):324-331. PubMed ID: 35674775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Senile systemic amyloidosis: clinical features at presentation and outcome.
    Pinney JH; Whelan CJ; Petrie A; Dungu J; Banypersad SM; Sattianayagam P; Wechalekar A; Gibbs SD; Venner CP; Wassef N; McCarthy CA; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD; Lachmann HJ
    J Am Heart Assoc; 2013 Apr; 2(2):e000098. PubMed ID: 23608605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.